Real-World Patterns of Peri-Procedural Antiplatelet Therapy and Concomitant Verapamil Use During Transradial Percutaneous Coronary Intervention

Why It Matters

Concurrent ticagrelor and verapamil may affect drug metabolism and bleeding risk, prompting need for pharmacokinetic and safety studies. Understanding these patterns helps clinicians optimize antiplatelet strategies for transradial PCI.

Key Takeaways

• Verapamil used in 98.5% of transradial PCI cases
• Ticagrelor administered in 33% of procedures
• 97% of ticagrelor patients also received verapamil
• Ticagrelor use dropped 15% between 2024‑2025
• Ticagrelor users younger, predominantly male

Pulse Analysis

Transradial percutaneous coronary intervention has become the default access route for most coronary procedures because it reduces bleeding and improves patient comfort. To mitigate radial artery spasm, operators routinely administer vasodilators such as verapamil, which relaxes smooth muscle and facilitates catheter navigation. Simultaneously, potent P2Y12 inhibitors like ticagrelor are favored for their rapid onset and superior platelet inhibition compared with clopidogrel. The convergence of these two drug classes in the peri‑procedural window creates a common exposure pattern that has received limited systematic scrutiny until now.

Ticagrelor is metabolized primarily by the CYP3A4 enzyme, and verapamil is a known moderate inhibitor of the same pathway. When co‑administered, verapamil can raise ticagrelor plasma concentrations, potentially intensifying antiplatelet effect and elevating bleeding risk, especially in older patients or those with renal impairment. Conversely, enhanced platelet inhibition may improve procedural outcomes by reducing thrombotic complications. Real‑world evidence showing that nearly one‑third of PCI cases involve this drug pair underscores the urgency of quantifying the net clinical impact through pharmacokinetic and outcome‑based research.

Clinicians should weigh the benefits of aggressive antiplatelet therapy against the pharmacologic interaction with verapamil, possibly adjusting ticagrelor dosing or selecting alternative vasodilators in high‑risk patients. Institutional protocols may incorporate routine monitoring of bleeding markers when the combination is used, and future randomized trials could compare ticagrelor‑verapamil versus clopidogrel‑verapamil strategies. As the data suggest a downward trend in ticagrelor adoption, cost considerations and evolving guideline recommendations may also shape prescribing habits. Ultimately, integrating these exposure patterns into decision‑making can refine safety and efficacy outcomes for transradial PCI.